RECOVER-ENERGIZE 플랫폼 프로토콜
RECOVER-ENERGIZE: SARS-CoV-2 감염(PASC) 급성 후유증의 운동 불내성에 대한 중재를 평가하기 위한 플랫폼 프로토콜
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes.
This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC).
The focus of this protocol is to assess interventions that can improve exercise capacity, daily activities tolerance, and quality of life in patients with PASC.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Study interventions will be added to the platform protocol as appendices. Each appendix will leverage all elements of the platform protocol, with additional elements described in the individual appendix. Study intervention appendices may be added or removed according to adaptive design and/or emerging evidence.
The platform protocol enrolls participants who meet study eligibility criteria. After completing initial screening assessments, eligible participants are assigned to one of the study intervention appendices that are actively enrolling. Participants must meet certain criteria within a specific appendix in order to be included in that appendix. Once assigned to an appendix, eligible participants are randomized to either the study intervention group or a control group.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35205
- University of Alabama at Birmingham
-
-
Arizona
-
Phoenix, Arizona, 미국, 85006
- Banner University Medical Center Phoenix
-
Tucson, Arizona, 미국, 85719
- Banner University Medical Center Tucson
-
-
California
-
Stanford, California, 미국, 94035
- Stanford University
-
Torrance, California, 미국, 90509
- Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- University of Colorado
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06520-8017
- Yale - New Haven Hospital
-
-
Florida
-
Jacksonville, Florida, 미국, 32209
- University of Florida College of Medicine Jacksonville
-
Miami, Florida, 미국, 33165
- Valencia Medical and Research Center
-
Miami, Florida, 미국, 33144
- Innovation Clinical Trials Inc.
-
-
Georgia
-
Atlanta, Georgia, 미국, 30303
- Grady Memorial Hospital (Emory)
-
Decatur, Georgia, 미국, 30030
- Emory Hope Clinic
-
-
Illinois
-
Chicago, Illinois, 미국, 60612
- Rush University Medical Center
-
Chicago, Illinois, 미국, 60608
- University of Illinois at Chicago
-
Evanston, Illinois, 미국, 60201
- North Shore University HealthSystem/Evanston Hospital
-
Peoria, Illinois, 미국, 61637
- Saint Francis Medical Center
-
-
Iowa
-
Waterloo, Iowa, 미국, 50701
- Cedar Valley Clinical Research
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- Kansas University Medical Center
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- University of Kentucky
-
-
Maine
-
Scarborough, Maine, 미국, 04074
- Maine Health Institute of Research
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, 미국, 02111
- Tufts Medical Center
-
Boston, Massachusetts, 미국, 02215
- Beth Israel Deaconess Med. Ctr.
-
-
Michigan
-
Detroit, Michigan, 미국, 48202
- Henry Ford Hospital
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- Mayo Clinic
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- Washington University School of Medicine
-
-
New Hampshire
-
Lebanon, New Hampshire, 미국, 03756
- Dartmouth Hitchcock Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87102
- University of New Mexico Health Sciences Center
-
-
New York
-
Brooklyn, New York, 미국, 11220
- NYU Langone Health/Brooklyn Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27514
- University of North Carolina Hospital
-
Durham, North Carolina, 미국, 27710
- Duke University Medical Center
-
-
Oregon
-
Portland, Oregon, 미국, 97239-3098
- Oregon Health and Science University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15213
- University of Pittsburgh
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57108
- Avera McKennan Hospital & University Health Center
-
-
Texas
-
Dallas, Texas, 미국, 75235
- Southwest Family Medicine Associates
-
Houston, Texas, 미국, 77030
- Houston Methodist Hospital
-
Houston, Texas, 미국, 77030
- University of Texas Health Science Center at Houston
-
-
Utah
-
Salt Lake City, Utah, 미국, 84132
- University of Utah
-
-
Vermont
-
Colchester, Vermont, 미국, 05446
- Vermont Lung Center, University of Vermont
-
-
West Virginia
-
Huntington, West Virginia, 미국, 25701
- University Physicians and Surgeons, Inc dba Marshall Health
-
Morgantown, West Virginia, 미국, 26506
- West Virginia Clinical and Translational Science Institute
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
≥ 18 years of age at the time of enrollment
-
Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by the Pan American Health Organization*
- Suspected* or probable SARS-CoV-2 infection will only be allowed if it occurred before May 1, 2021, and will be limited to no more than 10% of the study population. Otherwise, confirmed cases are required.
Suspected case of SARS-CoV-2 infection - Three options, A through C:
A. A person who meets the clinical OR epidemiological criteria. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Acute respiratory infection with history of fever or measured fever of ≥ 38°C; and cough; with onset within the last 10 days; and who requires hospitalization; or C. With no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test.
Probable case of SARS-CoV-2 infection:
A. A patient who meets clinical criteria above AND is a contact of a probable or confirmed case or is linked to a COVID-19 cluster.
Confirmed case of SARS-CoV-2 infection - Two options, A and B:
A. A person with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or B. Meeting clinical criteria AND/OR epidemiological criteria (See suspected case A above for criteria). With a positive professional use or self-test SARS- CoV-2 Antigen-Rapid Diagnostic Test.
-
Self-reported limitation to physical activity due to the presence of symptoms such as fatigue, shortness of breath, and/or PEM following a SARS-CoV-2 infection, that has persisted for at least 12 weeks and is present at the time of consent.
-
Willing, able, and agree to provide informed consent, complete questionnaires and outcome assessments, and participate in the study, including assigned intervention or control and study visits whether remote, hybrid, or in-person.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Known active acute SARS-CoV-2 infection ≤ 4 weeks prior to the consent.
- Known prior diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), not related to SARS-CoV-2 infection.
- Current or recent use (within the last 14 days) of a formal program utilizing one or more of the current study intervention(s) or similar intervention(s) to treat the underlying condition, unless a washout period is permitted per Appendices.
- Participation in another interventional clinical trial.
- Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Experimental: Appendix A - Cardiopulmonary Rehabilitation (Exercise Intolerance)
Appendix A is a randomized controlled trial designed to evaluate the effect of a 12-week personalized cardiopulmonary rehabilitation intervention on exercise tolerance in participants with PASC. Participants who meet eligibility criteria for Appendix A will be assigned to either Personalized Cardiopulmonary Rehabilitation (study intervention group) or Education (control group) in a 1:1 ratio. The intervention duration is 12 weeks with a follow-up period of 3 months (total study duration of 6 months). Anticipated enrollment is 360 participants. Details about Appendix A: Cardiopulmonary Rehabilitation (Exercise Intolerance) are available under NCT06404060. |
Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation. Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training. Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff. |
|
실험적: Experimental: Appendix B - Structured Pacing (PEM)
Appendix B is a randomized controlled trial designed to evaluate the effect of a 12-week Structured Pacing intervention on reducing the symptoms of post-exertional malaise (PEM) in participants with PASC. Participants who meet eligibility criteria for Appendix B will be assigned to either Structured Pacing (study intervention group) or Usual Care (control group) in a 1:1 ratio. The intervention duration is 12 weeks with a follow-up period of 3 months (total study duration of 6 months). Anticipated enrollment is 300 participants. Details about Appendix B: Structured Pacing (PEM) are available under NCT06404073. |
Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications. Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Total Number of Participants Enrolled in Each Appendix
기간: 6 months
|
Total number of participants enrolled in each Appendix will be reported. Appendix-specific outcome measure data will be reported under the associated NCT ID. |
6 months
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 연구 의자: Gary M Felker, MD, Duke Clinical Research Institute
- 연구 의자: Barry Make, MD, National Jewish Health
- 연구 의자: Lucinda Bateman, MD, Bateman Horne Center
- 연구 의자: Janna Friedly, MD, MPH, University of Washington
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- Pro00112409
- OT2HL156812 (미국 NIH 보조금/계약)
- NHLBI Grant to RTI (기타 보조금/기금 번호: RTI subcontracting with DCRI)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The summary of the results will be shared on the study website: https://recovercovid.org/
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .